HUTCHMED closes KRAS-EGFR antibody conjugate license to GSK outside China

HUTCHMED announced the closing of a license of its KRAS-EGFR antibody conjugate therapy to GSK for markets outside China.

Detected & updated continuously · Source: Nebula